Pharma Industry

Savings in the future on 10 prescription drugs for taxpayers and Medicare patients.

America's poorest seniors could soon find it much harder to get the medicines they need.

AAFP president weighs in on current issues in U.S. health care market.

The top news stories in medicine today.

Novo Nordisk says it is working to make more; FDA warns against too much of a good thing.

For some seniors living with chronic diseases, one particular reform may actually lead to higher out-of-pocket costs

Three largest pharmacy benefit manager executives testify in House Oversight Committee.

House Oversight Committee takes aim at pharmacy benefit managers.

PBMs counter that document is heavy on accusations but empty for evidence.

Some PBMs have ignored government compliance orders despite having two years to comply

The consolidation of health care is well underway, with PBMs making moves to keep and expand their control. But new models are emerging to offer hope for changing the health care industry for good.

Analysts ponder value, transparency and the effects of the Inflation Reduction Act.

Unpacking vaccine pricing: navigating policy, economics, and public health imperatives.

Rep. Greg Murphy, MD, discusses prior authorizations and other pending legislation in Washington.

Abortion and AI also in the mix at the national level.

Critics air concerns at White House roundtable as pharmacy benefit manager volley back.

More than half of the nation’s state top lawyers pen letter to leaders in House and Senate.

Change takes effect in 2025 and could benefit more than one million Medicare beneficiaries

PhRMA, U.S. Chamber warn of unintended consequences, market effects of negotiations.

Administration, HHS tout milestone day on road to lowering drug prices for beneficiaries.

It's time for pharmaceutical companies and others to innovate and disrupt the distribution side of treatment.

Prescription drug prices, vaccine costs are also key issues.

In 2024, beneficiaries could see savings per dose, according to new guidance on price increases relative to inflation.

Public-private partnerships will crumble, hurting drug innovation and eventually patients, Republicans say.